DIPHENHYDRAMINE HYDROCHLORIDE INJECTION

The Defense Logistics Agency awarded a delivery order under the base contract SPE2DX25D9822 to DMS PHARMACEUTICAL GROUP INC, identified by CAGE code 1UNB0, for the procurement of one box of DIPHENHYDRAMINE HYDROCHLORIDE INJECTION (NSN 6505016490647) at a total price of $43.38, with delivery required by July 20, 2026. The contract is structured as a firm-fixed-price commercial item acquisition governed by FAR 52.212-4 and associated clauses, including instructions to offerors and representations from commercial suppliers. Performance is FOB destination at USNS ABLE T-AGOS 20, FPO AP 96660, with the contractor responsible for all freight charges and delivery logistics, and acceptance is conducted by the Government upon arrival. The acquisition was set aside for small businesses, including HubZone, service-disabled veteran-owned, and women-owned small business categories, with the offeror qualifying under the 1,300 employee size standard, though no explicit socioeconomic certifications are documented. Payment is processed through the Defense Finance and Accounting Service in Columbus, Ohio, under Net 15 Fast Pay terms, with invoicing directed to the specified remit-to address. Contract administration is managed by the DLA Troop Support, Medical Supply Chain FSB in Philadelphia, with Lorinda Ferraiolo as the contracting officer and Catherine Gilbert as the administrative contact; no COR or COTR is designated. The parent contract has a $20 million IDIQ ceiling, but this delivery order is a standalone, non-option transaction with no quantity variance or extended terms. Special requirements include adherence to DLA Procurement Notes C19 and C20 for administrative documentation via the FLEET MILSTRIP system, and compliance with DLA’s official unit-of-issue specifications. No explicit packaging, marking, or inspection standards beyond contract conformity are detailed, and while an attachment referencing backup administrative procedures is included, its full contents are not available. No evaluation factors, technical specifications beyond product identification, or security requirements are specified in the provided documentation.